2. Search Result
Search Result
Results for "

Immunoglobulin A nephropathy

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-127105
    Iptacopan
    Maximum Cited Publications
    13 Publications Verification

    LNP023

    		 Complement System Metabolic Disease Inflammation/Immunology
    Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
    Iptacopan
  • HY-P99901
    Sibeprenlimab

    VIS649

    		 SARS-CoV Inflammation/Immunology Cancer
    Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
    Sibeprenlimab
  • HY-127105A
    Iptacopan hydrochloride
    Maximum Cited Publications
    13 Publications Verification

    LNP023 hydrochloride

    		 Complement System Metabolic Disease Inflammation/Immunology
    Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
    Iptacopan hydrochloride
  • HY-P5309
    IgA1 Peptide GN5

    		Biochemical Assay Reagents Inflammation/Immunology
    IgA1 Peptide GN5 is a synthetic glycopeptide and can be used for detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients .
    IgA1 Peptide GN5
  • HY-P5309A
    IgA1 Peptide GN5 TFA

    		Biochemical Assay Reagents Inflammation/Immunology
    IgA1 Peptide GN5 (TFA) is a synthetic glycopeptide and can be used for detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients .
    IgA1 Peptide GN5 TFA
  • HY-P991153
    Potravitug

    		Virus Protease Infection
    Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
    Potravitug
  • HY-200854
    Iptacopan hydrochloride hydrate

    LNP023 hydrochloride hydrate

    		 Complement System Metabolic Disease Inflammation/Immunology
    Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
    Iptacopan hydrochloride hydrate
  • HY-127105B
    Iptacopan TFA

    LNP023 TFA

    		 Complement System Metabolic Disease Inflammation/Immunology
    Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
    Iptacopan TFA

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: